Author:
Cho, H-J 1; Park, A 2; Park, M-N 2; Lee, E 1; Yoon, J 1; Suh, N 2; Park, H 2; Oh, Y-M 3; Yu, J 1
Author address:
1 Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2 Asan Institute for Life Sciences and University of Ulsan College of Medicine, Seoul, Korea; 3 Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway
Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Full conference title:
European Academy of Allergy and Clinical Immunology Congress 2016
Date: 5 August 2020
Abstract:
Background: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease. Mesenchymal stem cells have been known to have an immunomodulatory effect. There is little information about the effect of MSC on the treatment of atopic dermatitis.
Method: We applied Aspergillus fumigatus (Af) extract (40 lg) to the dorsal skin of BALB/c mice 5 times a week repeatedly with an interval of 2 weeks to induce atopic dermatitis-like skin lesions. Umbilical cord derived mesenchymal stem cells (UCMSCs) (2 9 107 /ml) were injected subcutaneously at the last day of Af application. Clinical score and transepidermal water loss (TEWL) were assessed and histology was examined at 1, 5, and 10 days after injection of UC-MSCs. To evaluate a dosedependent effect, UC-MSCs of 4 x 107 /ml were also injected.
Results: The clinical score and TEWL were decreased at 5 days after subcutaneous injection of UC-MSCs. Moreover, UC-MSCs inhibited eosinophilic infiltration in skin lesions, and decreased the levels of total IgE. However, the effects of UC-MSCs were not dose dependent.
Conclusion: UC-MSCs alleviated atopic dermatitis-skin lesion in a murine model, which suggests therapeutic potential of UC-MSCs for human atopic dermatitis.
Abstract Number: 591
Link to conference website:
Link Conference abstract:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
D Luptáková1*, RH Patil1,2, R Dobiáš3,4, DA Stevens5,6, T Pluháček1,2, A Palyzová1, A Škríba1, V Havlíček1,2
2022
23
-
v
Y Bahri*, S Ben.Belgacem, Y Maatouk, A Ben.Salah, M Mastouri
2022
22
-
v
Y Bahri*, S Ben.Belgacem, Y Maatouk, A Ben.Salah, M Mastouri
2022
21
-
v
A Knaz1, A Omrane1, H Chouaieb2, M Chatti2, R Mrassi2, S Ismail2, M Ben Seif2, W Benzarti1, MA Ayed1, A Abdelghani1, A Hayouni1, S Aissa1, I Gargouri1, A Fathallah2*
2022
20
-
v
A Azzabi1, O Mahfoudh1, N Ben Aicha1, W Sahtout1, A Ayadi2, Z Lajmi3, M Smida4, H Chouaieb4, M Chatti4, S Ismail4, R Boukadida1, F Sabri 1, S Ben Amor1, D Zellama1, S Hmissa3, H Kochtali2, A Fathallah4*, Y Guedri1, A Achour1
2022
19
-
v
M Smida1, A Meherzi2, H Chouaieb1, M Chatti1, M Ben Seif1, R Hajlaoui1, M Abdelkefi2, A Fathallah1*
2022
18
-
v
M Sahu1*, M Shah2, MV Rao3, VR Kola4, HK Boorugu5, AR Punjani6, RV Kumar7, S Kumar8, M Manusrut9, RK Rathod10, HK Gonuguntla11, GK Yedlapati12, GR Mallu13, YS Reddy14, RN KomalKumar15, GS Jaishetwar16, KR Balasubramoniam17, SCR Kumar18, B Nagaraju19, PR Sahoo20
2022
17
-
Chronic pulmonary aspergillosis among presumed tuberculosis patients at a tertiary hospital in Ghana
v
BK Ocansey1*, A Adjei2, H Gbadamosi3, C Kosmidis1,4, J Afriyie-Mensah2,5, JO Opintan6, DW Denning1
2022
16
-
v
CD de La Porte1*, CP Provost2, AS Serris1, AC Coste3, MB Bougnoux4, RB Herbrecht5, VB Bru6, FA Ader7, FP Persat8, EC Canet9, FM Morio10, BD Denis11, AA Alanio12, LL Lelièvre13, SC Cassaing14, RS Sonneville15, LM Millon16, OL Lortholary1, ON Naggara2, FL Lanternier1, French Cerebral Mucormycosis Study Group
2022
14